Literature DB >> 1969717

The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat.

K Khuenl-Brady1, K P Castagnoli, P C Canfell, J E Caldwell, S Agoston, R D Miller.   

Abstract

The neuromuscular blocking effects and pharmacokinetics of ORG 9426, 1.5 mg/kg and ORG 9616, 1.2 mg/kg iv, two new nondepolarizing neuromuscular blocking drugs, were studied in 28 cats (i.e., 14 cats with each drug) with and without renal pedicle ligation. A gas chromatographic assay was used to determine the concentrations of ORG 9426 and ORG 9616 and its desacetyl metabolites in plasma, urine, bile, and liver. The duration of neuromuscular blockade of both drugs was not altered by ligation of renal pedicles. Plasma clearance of ORG 9426 was slower in cats with ligated renal pedicles (P less than 0.01). With ORG 9616, mean elimination half-life was slower and mean residence time longer in cats with renal pedicle ligation. Otherwise, there was no significant differences with any pharmacokinetic variables in cats with and without renal pedicle ligation. Only 8.7 +/- 5.7% (SD) and 6.0 +/- 2.8% of an injected dose of ORG 9426 and ORG 9616 was excreted into the urine, respectively. Conversely, 54.4 +/- 9.2% and 52.4 +/- 9.2% of an injected dose of ORG 9426 and 35.7 +/- 12.2% and 46.8 +/- 9.7% of ORG 9616 were excreted into the bile in cats without and with renal pedicle ligation, respectively. Finally, 21.3 +/- 6.5% and 33.5 +/- 15.6% of ORG 9426 and 14.0 +/- 3.2% and 18.1 +/- 5.6% of ORG 9616 were in the liver 6 h after injection in cats without and with renal pedicle ligation respectively. The authors were able to account for the biodisposition of 84.4% and 85.9% of an injected dose of ORG 9426 in cats without and with renal pedicle ligation respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969717     DOI: 10.1097/00000542-199004000-00016

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  19 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

3.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

4.  The Pringle maneuver reduces the infusion rate of rocuronium required to maintain surgical muscle relaxation during hepatectomy.

Authors:  Akira Kajiura; Osamu Nagata; Masamitsu Sanui
Journal:  J Anesth       Date:  2018-04-27       Impact factor: 2.078

Review 5.  Clinical pharmacokinetics of rocuronium bromide.

Authors:  K S Khuenl-Brady; H Sparr
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

6.  Dose requirements of continuous infusion of rocuronium and atracurium throughout orthotopic liver transplantation in humans.

Authors:  Xiao-Chuan Weng; Liang Zhou; Yin-Yan Fu; Sheng-Mei Zhu; Hui-Liang He; Jian Wu
Journal:  J Zhejiang Univ Sci B       Date:  2005-09       Impact factor: 3.066

7.  Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats.

Authors:  Lonneke M Staals; Hans D de Boer; Jan van Egmond; Frank Hope; Francien van de Pol; Anton H Bom; Jacques J Driessen; Leo H D J Booij
Journal:  J Anesth       Date:  2011-01-12       Impact factor: 2.078

Review 8.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 9.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.